Suzuki Issei, Kijima Toshiki, Takada-Owada Atsuko, Nakamura Gaku, Uematsu Toshitaka, Sakamoto Kazumasa, Nishihara Daisaku, Ishida Kazuyuki, Kamai Takao
Departments of Urology Dokkyo Medical University Shimotsuga Tochigi Japan.
Department of Diagnostic Pathology Dokkyo Medical University Shimotsuga Tochigi Japan.
IJU Case Rep. 2021 Aug 24;4(6):412-416. doi: 10.1002/iju5.12362. eCollection 2021 Nov.
We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy.
A 50-year-old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left-sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8 T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence-free without any additional treatment for eight months.
For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery.
我们报告了一例肾细胞癌合并腔静脉血栓形成的病例,该病例在术前使用阿维鲁单抗联合阿昔替尼治疗后血栓明显缩小,从而便于进行肾切除术并摘除血栓。
一名50岁男性因自发性肾破裂被送往急诊室,被诊断为左侧肾细胞癌伴IV级肿瘤血栓。经导管动脉栓塞止血后,由于患者身体状况不佳且可能存在腹膜后肿瘤播散,前期手术被认为不可行,遂开始使用阿维鲁单抗联合阿昔替尼治疗。经过四个治疗周期后,血栓缩小至II级,随后进行了肾切除术并摘除血栓。组织学分析显示血栓中有大量CD8 T细胞浸润,提示免疫治疗有效。他在未接受任何额外治疗的情况下已无复发地存活了八个月。
对于合并腔静脉血栓形成的局部晚期肾细胞癌,术前使用阿维鲁单抗联合阿昔替尼进行联合治疗可能是促进根治性手术的一种选择。